Semax vs Selank: A Research Literature Comparison
Two Russian heptapeptides, two different parents
Semax vs Selank is the comparison the Russian peptide literature keeps returning to. Both compounds are synthetic heptapeptides. Both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Both are administered intranasally in clinical practice. Both carry a Pro-Gly-Pro tail for proteolytic stability. But their parent hormones differ, and that difference defines their clinical positioning.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is built on the ACTH 4-7 fragment with a Pro-Gly-Pro stabilizing extension. Its clinical positioning is nootropic and neuroprotective — stroke recovery, cognitive impairment, optic nerve disease [1][7]. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is built on the Tuftsin tetrapeptide with the same Pro-Gly-Pro tail. Its clinical positioning is anxiolytic — generalized anxiety disorder, asthenic disorders, withdrawal syndromes in Russian psychiatric practice.
Anxiety endpoints: Semax vs Selank
Selank, a Tuftsin analog, was designed as an anxiolytic. Russian clinical trials in generalized anxiety disorder report measurable improvement in HAM-A scores with intranasal Selank versus placebo and versus benzodiazepine comparators, with the advantage of no sedation and no withdrawal syndrome. Semax is primarily nootropic and neuroprotective. The Semax record in anxiety is much thinner — the rodent BDNF and serotonergic data could plausibly contribute to stress-related symptom improvement, but published controlled trials in primary anxiety populations are not the strength of the Semax literature [6]. Published trials position Selank as the anxiety-focused peptide of the pair.
Cognitive clarity: Semax vs Selank
For cognitive symptoms — brain fog, attention drift, post-illness cognitive recovery — the Semax mechanism aligns more directly with published cognitive endpoints. The BDNF-NGF-TrkB cascade in hippocampus and basal forebrain [3], the striatal monoaminergic activation [6], the EEG signal in healthy volunteers [23] — all map to the cognitive register. Selank's effect on focus is described in the Russian literature as indirect, mediated by anxiolytic action: anxiety down, attention up. The two mechanisms can converge on a similar subjective outcome through very different pathways.
Combined Selank and Semax in the literature
Some Russian clinical protocols pair Selank and Semax for complementary anxiolytic-plus-nootropic profiles, particularly in cerebrovascular insufficiency populations with comorbid anxiety. The pairing is described in clinical reviews and case-series literature rather than in randomized controlled trials. Controlled Western head-to-head comparative human data is limited. The pairing rationale is mechanistic — the two peptides act on distinct pathways (Semax through neurotrophic and monoaminergic signaling, Selank through Tuftsin-receptor and GABAergic mechanisms) and the side-effect profiles do not appear to overlap problematically in the published case reports.
Where the comparison matters and where it does not
Both compounds share a clinical signature that distinguishes them from many CNS-active drugs: no classical stimulant action, no benzodiazepine-style sedation, no documented withdrawal, no HPA-axis activation. That signature is what makes the comparison meaningful in the Russian nootropic and anxiolytic literature. It is also what makes the Western evidence picture frustrating — neither peptide has cleared Western Phase 3 trials, neither is FDA approved, and the comparison rests on Russian clinical practice plus rodent mechanism work. The full Semax mechanism of action reading covers the neurotrophic substrate in detail.